Safety Profile:

• Two-dose series was well tolerated with no dose-safety concerns
• Adverse reactions were mild, and most commonly reported was pain at injection site

Method:

• Randomized and double-blind, placebo-controlled
• Consisted of 600 participants; all healthy adults with ages ranging from 18-59
• Two-dose series of 0.5 mL, 0.6 mL, or placebo

Performance:

• The smaller dose (0.5 mL), had 92.4% seroconversion after 2 weeks, and 97.4% after 4 weeks
• Antigen binding antibody levels ranged from 23.8 to 65.4 after 28 days depending on dosage and schedule